Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents

Journal of the National Cancer Institute

Volumn 90, Issue 21, 1998, Pages 1648-1653

  Joseph, Ingrid B J K ^a   Isaacs, John T ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; GENISTEIN; PENTOXIFYLLINE; ROQUINIMEX; THALIDOMIDE;

ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BLOOD FLOW;

EID: 0032483682     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/90.21.1648     Document Type: Article

References (36)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1:27-31.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
3. Folkman J. Tumor angiogenesis. In: Mendelssohn J, Howley P, Israel M, Liotta LA, editors. The molecular basis of cancer. Philadelphia: Saunders; 1995. p. 206-32.
4. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Ann Rev Physiol 1991;53:217-39.
5. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-22.
6. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab Invest 1984;51:635-42.
7. Polverini PJ. Macrophage induced angiogenesis: a review In: Sorg C, editor. Cytokines and macrophage-derived cell regulatory factors. Basel: Karger Verlag; 1989. p. 54-73.
8. Pepper MS, Vassalli JD, Montesano R, Orci L. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells. J Cell Biol 1987;105(6 Pt 1):2535-11.
9. Sumiyoshi K, Serizawa K, Urano T, Takada Y, Takada A, Baba S. Plasminogen activator system in human breast cancer. Int J Cancer 1992; 50:345-8.
10. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994; 69:398-405.
11. Hildenbrand R, Dilger I, Horlin A, Stutte HJ. Urokinase plasminogen activator induces angiogenesis and tumor vessel invasion in breast cancer. Arch Res Pract 1995;191:403-9.
12. Foekens JA, Buessecker F, Peters HA, Krainick U, van Putten WL, Look MP, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995;55:1423-7.
13. Baker MS, Bleakley P, Woodrow GC, Doe WF. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation. Cancer Res 1990;50: 4676-84.
14. Hamilton JA, Whitty GA, Stanton H, Wojta J, Gallichio M, McGrath K, et al. Macrophage colony-stimulating factor and granulocyte-macrophage colony-stimulating factor stimulate the synthesis of plasminogen-activator inhibitors by human macrophages. Blood 1993; 82:3616-21.
15. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
16. Ichikawa T, Lamb JC, Christensson PI, Hartley-Asp B, Isaacs JT. The antitumor effects of the quinolene-3-carboxamide Linomide on Dunning R-3327 rat prostatic cancers. Cancer Res 1992;52:3022-28.
17. Vukanovic J, Isaacs JT. Human prostatic cancer cells are sensitive to programmed (apoptotic) death induced by the antiangiogenic agent Linomide. Cancer Res 1995;55:3517-20.
18. Joseph IB, Vukanovic J, Isaacs JT. Antiangiogenic treatment with Linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents. Cancer Res 1996;56: 3404-8.
19. Vukanovic J, Passaniti A, Hirata T, Traystman RJ, Hartley-Asp B, Isaacs JT. Antiangiogenic effects of the quinoline-3-carboxamide Linomide. Cancer Res 1993;3:1833-7.
20. Vukanovic J, Hartley-Asp B, Isaacs JT. Inhibition of tumor angiogenesis and the therapeutic ability of Linomide against rat prostatic cancers. Prostate 1995;26:235-46.
21. Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res 1995;55:1499-504.
22. Joseph IB, Isaacs JT. The antiangiogenic agent, Linomide inhibits tumor necrosis factor-α secretion via inhibition of its synthesis. Prostate 1996;29:183-90.
23. Hartley-Asp B, Vukanovic J, Joseph IB, Strandgarden K, Polacek J, Isaacs JT. Anti-angiogenic treatment with Linomide as adjuvant to surgical castration in experimental prostate cancer. J Urol 1997;158:902-7.
24. Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990;50:3748-53.
25. Joseph IB, Isaacs JT. Potentiation of the anti-angiogenic ability of Linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers. Cancer Res 1997; 57:1054-7.
26. Joseph IB, Nelson JB, Denmeade SR, Isaacs JT. Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. Clin Cancer Res 1997;3: 2507-11.
27. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91: 4082-5.
28. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor a by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
29. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, et al. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993;90: 2690-1.
30. Ambrus JL, Ambrus CM, Forgach P, Stadler S, Halpern J, Sayyid S, et al. Studies on tumor induced angiogenesis. EXS 1992;61:436-44.
31. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-81.
32. Beaty CD, Franklin TL, Vehara Y, Wilson CB. Lipopolysaccharide-induced cytokine production in human monocytes: role of tyrosine phosphorylation in transmembrane signal tranduction. Eur J Immunol 1994;24:1278-84.
33. Billstrom A, Kinnby B, Lecander I, Astedt B. Production of plasminogen activator inhibitor type-2 in human peripheral blood monocytes upregulated in vitro by the quinoline-3-carboxamide, Linomide. Fibrinolysis 1996;10: 277-83.
34. Guo D, Jia Q, Song HY, Warren RS, Donner DB. Vascular endothelial growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 1995; 270:6729-33.
35. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
36. Parenti A, Donnini S, Morbidelli L, Granger HJ, Ziehe M. The effect of Linomide on the migration and the proliferation of capillary endothelial cells elicited by vascular endothelial growth factor. Br J Pharmacol 1996;119: 619-21.